CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale CFO and Treasurer sold 1,428 shares at $19.48 ($27,817)
- 4 Open-market sale COO and Secretary sold 1,427 shares at $19.49 ($27,812)
- 4 Open-market sale Chief Medical Officer sold 1,428 shares at $19.48 ($27,817)
- 4 Open-market sale President and CEO sold 4,807 shares at $19.48 ($93,640)
- 4/A Exercise or conversion CFO and Treasurer acquired 4,250 shares (option exercise)
- 4/A Exercise or conversion COO and Secretary acquired 4,250 shares (option exercise)
- 4/A Exercise or conversion Chief Medical Officer acquired 4,250 shares (option exercise)
- 4/A Exercise or conversion President and CEO acquired 14,315 shares (option exercise)
- 4 Open-market sale 10% owner sold 3,894,764 shares at $20.25 ($78,868,971)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 16 of 22 · 436 filings